Olatec Therapeutics

Olatec Therapeutics is a clinical-stage biotech pioneering the development of oral NLRP3 inhibitors, a novel class of anti-inflammatory therapeutics. Its lead asset, dapansutrile, has demonstrated clinical benefit and a clean safety profile in human studies, targeting conditions from arthritis to heart failure and neurodegenerative diseases. The company boasts a deep pipeline of approximately 40 candidates and a robust intellectual property portfolio of over 180 patents globally. Led by an experienced team with co-founder Damaris Skouras at the helm and scientific luminary Dr. Charles Dinarello guiding R&D, Olatec is positioned to capitalize on the significant unmet need in inflammasome-mediated diseases.

Platform of oral, small-molecule NLRP3 inflammasome antagonists that selectively inhibit the production of pro-inflammatory cytokines IL-1β and IL-18.

The NLRP3 inhibitor field is competitive and rapidly evolving, with multiple biotech (e.g., NodThera, Inflazome) and large pharma players (Novartis, Roche) advancing candidates. Olatec's differentiation lies in the clinical experience and clean safety profile of its oral lead compound, dapansutrile, and its extensive IP portfolio.